ANO9 regulates PD‐L2 expression and binding ability to PD‐1 in gastric cancer

Katsurahara, Keita; Shiozaki, Atsushi; Kosuga, Toshiyuki; Shimizu, Hiroki; Kudou, Michihiro; Arita, Tomohiro; Konishi, Hirotaka; Komatsu, Shuhei; Kubota, Takeshi; Fujiwara, Hitoshi; Okamoto, Kazuma; Kishimoto, Mitsuo; Konishi, Eiichi; Otsuji, Eigo

doi:10.1111/cas.14796

Cited by 12 publications

(7 citation statements)

References 45 publications

(62 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IFN-γ signaling has been shown to be involved in regulating not only the expression level of PD-L1 414 but also the binding affinity of PD-L2 to PD-1. 415 Moreover, PD-L1 expression can be stimulated by inhibition of autophagy via the IFN-γ signaling pathway, 414 , 416 implying that pharmacological modulation of autophagy may be a novel strategy for improving the efficacy of PD-L1 blockade. On the other hand, miR-105-5p was found as a negative regulator of PD-L1 expression, highlighting it as a potential biomarker for PD-1/PD-L1 immunotherapy and a target for combinational regimen.…”

Section: Signaling Pathways In Gastric Cancer and Therapeutic Implica...mentioning

confidence: 99%

Signaling pathways and therapeutic interventions in gastric cancer

Lei

Teng

Chen

et al. 2022

Sig Transduct Target Ther

View full text Add to dashboard Cite

Gastric cancer (GC) ranks fifth in global cancer diagnosis and fourth in cancer-related death. Despite tremendous progress in diagnosis and therapeutic strategies and significant improvements in patient survival, the low malignancy stage is relatively asymptomatic and many GC cases are diagnosed at advanced stages, which leads to unsatisfactory prognosis and high recurrence rates. With the recent advances in genome analysis, biomarkers have been identified that have clinical importance for GC diagnosis, treatment, and prognosis. Modern molecular classifications have uncovered the vital roles that signaling pathways, including EGFR/HER2, p53, PI3K, immune checkpoint pathways, and cell adhesion signaling molecules, play in GC tumorigenesis, progression, metastasis, and therapeutic responsiveness. These biomarkers and molecular classifications open the way for more precise diagnoses and treatments for GC patients. Nevertheless, the relative significance, temporal activation, interaction with GC risk factors, and crosstalk between these signaling pathways in GC are not well understood. Here, we review the regulatory roles of signaling pathways in GC potential biomarkers, and therapeutic targets with an emphasis on recent discoveries. Current therapies, including signaling-based and immunotherapies exploited in the past decade, and the development of treatment for GC, particularly the challenges in developing precision medications, are discussed. These advances provide a direction for the integration of clinical, molecular, and genomic profiles to improve GC diagnosis and treatments.

show abstract

Section: Signaling Pathways In Gastric Cancer and Therapeutic Implica...mentioning

confidence: 99%

Signaling pathways and therapeutic interventions in gastric cancer

Lei

Teng

Chen

et al. 2022

Sig Transduct Target Ther

View full text Add to dashboard Cite

show abstract

“…Anoctamins have critical roles in many pathologies such as cancer, muscular dystrophy, spinocerebellar ataxia, bleeding disorders and neurological disease (Duran and Hartzell, 2011;Kunzelmann et al, 2011;Benarroch, 2017). In cancers, anoctamins were found to affect cancer progression, increase cell proliferation, migration and invasion (Xuan et al, 2019;Pinto et al, 2020;Katsurahara et al, 2021). In teleost fish, anoctamin expression is found in enteric neuronal subpopulations (Uyttebroek et al, 2013) and is related to rhythmic contractions of the gastrointestinal tract (Brijs et al, 2016).…”

Section: Discussionmentioning

confidence: 99%

Post-translational protein deimination signatures in sea lamprey (Petromyzon marinus) plasma and plasma-extracellular vesicles

Rast

D’Alessio

Kraev

et al. 2021

Developmental & Comparative Immunology

View full text Add to dashboard Cite

“…Over the past decade, one of the most important breakthroughs in cancer treatment has been immune checkpoint blockage (ICB) of programmed cell death-1 (PD-1). In GC, we have observed tumor suppressive effects following the genetic knockdown of ANO9 with siRNA technology, such as decreased proliferation, and increased apoptosis (Katsurahara et al, 2021). The results of microarray and IHC indicated that ANO9 regulates programmed cell death 1 ligand 2 (PD-L2) and binding ability to PD-1 via interferon (IFN)-related genes, suggesting that ANO9 has potential as a biomarker and target of ICB for GC.…”

Section: Chloride (Cl − ) Channelsmentioning

confidence: 99%

Roles of Ion and Water Channels in the Cell Death and Survival of Upper Gastrointestinal Tract Cancers

Shiozaki

Marunaka

Otsuji

2021

Front. Cell Dev. Biol.

Self Cite

View full text Add to dashboard Cite

Ion and water channels were recently shown to be involved in cancer cell functions, and various transporter types have been detected in upper gastrointestinal tract (UGI) cancers. Current information on the expression and roles of these channels and transporters in the death and survival of UGI cancer cells was reviewed herein, and the potential of their regulation for cancer management was investigated. Esophageal cancer (EC) and gastric cancer (GC) cells and tissues express many different types of ion channels, including voltage-gated K+, Cl–, and Ca2+, and transient receptor potential (TRP) channels, which regulate the progression of cancer. Aquaporin (AQP) 1, 3, and 5 are water channels that contribute to the progression of esophageal squamous cell carcinoma (ESCC) and GC. Intracellular pH regulators, including the anion exchanger (AE), sodium hydrogen exchanger (NHE), and vacuolar H+-ATPases (V-ATPase), also play roles in the functions of UGI cancer cells. We have previously conducted gene expression profiling and revealed that the regulatory mechanisms underlying apoptosis in ESCC cells involved various types of Cl– channels, Ca2+ channels, water channels, and pH regulators (Shimizu et al., 2014; Ariyoshi et al., 2017; Shiozaki et al., 2017, 2018a; Kobayashi et al., 2018; Yamazato et al., 2018; Konishi et al., 2019; Kudou et al., 2019; Katsurahara et al., 2020, 2021; Matsumoto et al., 2021; Mitsuda et al., 2021). We have also previously demonstrated the clinicopathological and prognostic significance of their expression in ESCC patients, and shown that their pharmacological blockage and gene silencing had an impact on carcinogenesis, indicating their potential as targets for the treatment of UGI cancers. A more detailed understanding of the molecular regulatory mechanisms underlying cell death and survival of UGI cancers may result in the application of cellular physiological methods as novel therapeutic approaches.

show abstract

ANO9 regulates PD‐L2 expression and binding ability to PD‐1 in gastric cancer

Cited by 12 publications

References 45 publications

Signaling pathways and therapeutic interventions in gastric cancer

Signaling pathways and therapeutic interventions in gastric cancer

Post-translational protein deimination signatures in sea lamprey (Petromyzon marinus) plasma and plasma-extracellular vesicles

Roles of Ion and Water Channels in the Cell Death and Survival of Upper Gastrointestinal Tract Cancers

Contact Info

Product

Resources

About